SCHEMBL2007995

SCHEMBL2007995

COCOc1ccc(C2COc3cc(OCOC)ccc3C2O)cc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.46
USP2 O75604 1/20 0.44
PPARG P37231 8/20 0.41
PPARD Q03181 8/20 0.41
FFAR1 O14842 5/20 0.41
ESR1 P03372 2/20 0.39
ESR2 Q92731 2/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP19A1 P11511 2/20 0.38
PPARA Q07869 1/20 0.38
LTB4R Q15722 1/20 0.38
LTB4R2 Q9NPC1 1/20 0.38
PTPN1 P18031 1/20 0.37
ROR1 Q01973 1/20 0.37
DRD2 P14416 1/20 0.36
DRD3 P35462 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2742797 0.92 CYP3A4 (0.43) CYP3A4USP2PPARGPPARDFFAR1
SCHEMBL19418882 0.83 CYP3A4 (0.54) CYP3A4USP2MAPTMAPK1TDP1
SCHEMBL12946428 0.82 CYP3A4 (0.47) CYP3A4USP2PPARGPPARDFFAR1
SCHEMBL24288953 0.81 CA2 (0.54) PPARGPPARDFFAR1ESR1ESR2
SCHEMBL5854087 0.80 PPARG (0.40) CYP3A4USP2PPARGPPARDFFAR1
SCHEMBL12914758 0.79 CA2 (0.50) CYP3A4USP2FFAR1ESR1ESR2
SCHEMBL2070035 0.77 CYP3A4 (0.53) CYP3A4USP2ESR1ESR2MAPT
SCHEMBL7500860 0.77 CYP3A4 (0.53) CYP3A4USP2ESR1ESR2MAPT
SCHEMBL2070036 0.77 CYP3A4 (0.53) CYP3A4USP2ESR1ESR2MAPT
SCHEMBL19418887 0.77 CYP3A4 (0.45) CYP3A4USP2PPARGPPARDFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103641808-B The enantioselective hydrogenation method of chromene GIRINDUS AMERICA INC. (US) 2016-04-20 CN disclosed
CN-103755675-B The enantioselective hydrogenation method of chromene GIRINDUS AMERICA INC. (US) 2015-11-18 CN disclosed
EP-1919887-B1 METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES GIRINDUS AMERICA INC (US) 2015-02-18 EP disclosed
CN-101535286-B Process for the enantioselective hydrogenation of chromenes GIRINDUS AMERICA INC 2014-05-07 CN disclosed
US-8716497-B2 Method for enantioselective hydrogenation of chromenes CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2014-05-06 US disclosed
US-8716497-B2 Method for enantioselective hydrogenation of chromenes CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2014-05-06 US disclosed
CN-103755675-A Method for enantioselective hydrogenation of chromenes GIRINDUS AMERICA INC 2014-04-30 CN disclosed
CN-103641808-A Method for enantioselective hydrogenation of chromenes GIRINDUS AMERICA INC 2014-03-19 CN disclosed
US-20130116450-A1 METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES GIRINDUS AMERICA, INC. (US) 2013-05-09 US disclosed
US-20130116450-A1 METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES GIRINDUS AMERICA, INC. (US) 2013-05-09 US disclosed
US-20100069653-A1 METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES Children hospital medical center (US) 2010-03-18 US disclosed
CN-101535286-A Process for the enantioselective hydrogenation of chromenes GIRINDUS AMERICA INC (US) 2009-09-16 CN disclosed
US-7528267-B2 Method for enantioselective hydrogenation of chromenes GIRINDUS AMERICA, INC. (US) 2009-05-05 US disclosed
US-7528267-B2 Method for enantioselective hydrogenation of chromenes GIRINDUS AMERICA, INC. (US) 2009-05-05 US disclosed
US-7528267-B2 Method for enantioselective hydrogenation of chromenes GIRINDUS AMERICA, INC. (US) 2009-05-05 US disclosed
EP-1919887-A2 METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES Girindus America, Inc. (US) 2008-05-14 EP disclosed
WO-2007016423-A2 METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES GIRINDUS AMERICA INC. (US) 2007-02-08 WO disclosed
US-20070027329-A1 Method for enantioselective hydrogenation of chromenes AUSIO PHARMACEUTICALS, LLC 2007-02-01 US disclosed
US-20070027329-A1 Method for enantioselective hydrogenation of chromenes AUSIO PHARMACEUTICALS, LLC 2007-02-01 US disclosed
US-20070027329-A1 Method for enantioselective hydrogenation of chromenes AUSIO PHARMACEUTICALS, LLC 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116450-A1 METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES HRH3, HRH2, CHD8 CYP3A4 487/4885USP2 2532/4885PPARG 256/4885
US-20070027329-A1 Method for enantioselective hydrogenation of chromenes HRH3, HRH2, CHD8 CYP3A4 487/4885USP2 2532/4885PPARG 256/4885
US-20100069653-A1 METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES HRH3, HRH2, CHD8 CYP3A4 487/4885USP2 2532/4885PPARG 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.